Parkinson's Disease: Current and Future Therapeutics and Clinical Trials
Cambridge University Press, 3/31/2016
EAN 9781107053861, ISBN10: 1107053862
Hardcover, 400 pages, 25.3 x 19.4 x 2.1 cm
Language: English
Parkinson's disease is no longer considered only a motor disorder. It has become evident that the pathological changes are broad, the progression seems to follow a pattern suggesting transynaptic transmission via templation of proteins in a prion-like fashion, and that these pathological changes usually antedate the motor symptoms by decades. This book emphasizes treatment options for Parkinson's disease, critically assessing pharmacologic and surgical interventions for all aspects of the disease. Evidence from randomized controlled clinical trials is highlighted to develop practical recommendations for clinical practice. Lessons learnt from clinical trials – and controversies and future challenges – are all addressed. Readers will find the necessary clinical and scientific foundations for the understanding of the disease, the underpinnings of the pathological processes, the identification of disease biomarkers, and the basis for solid therapeutics. Chapters are authored by an international team of specialists who bring their expertise to improving the management of this disease.
Part I. The Pharmacological Basis for Parkinson's Disease Treatment
1. The pharmacological basis of Parkinson's disease therapy
an overview
2. Anticholinergic agents in the management of Parkinson's disease
3. Amantadine and antiglutamatergic drugs in the management of Parkinson's disease
4. Monoamine oxidase inhibitors in the management of Parkinson's disease
5. Oral dopamine agonists in the anagement of Parkinson's disease
6. Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson's disease
7. Oral and infusion levodopa therapy in the management of Parkinson's disease
8. Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease
9. Experimental pharmacological agents in the management of Parkinson's disease
Part II. Management of Non-Motor Symptoms of Parkinson's Disease
10. Management of autonomic dysfunction in Parkinson's disease
11. Management of cognitive impairment in Parkinson's disease
12. A neurobehavioralist approach to the management of cognitive impairment in Parkinson's disease
13. Management of disease-related behavioral disturbances in Parkinson's disease
14. Management of treatment-related behavioral disturbances in Parkinson's disease
15. Management of sleep disorders in Parkinson's disease
16. Management of pain and euromuscular complications in Parkinson's disease
Part III. Surgical Management of Parkinson's Disease
17. Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease
18. Deep brain stimulation of the globus pallidus internus in the management of Parkinson's disease
19. Deep brain stimulation of the subthalamic nucleus in the management of Parkinson's disease
20. Deep brain stimulation of the thalamic ventral intermediate nucleus in the management of Parkinson's disease
21. Emerging targets and other stimulation-related procedures in the management of Parkinson's disease
Part IV. Clinical Trials in Parkinson's Disease
Lessons, Controversies and Challenges
22. Rating scales and clinical outcome measures in the evaluation of patients with Parkinson's disease
23. Functional imaging markers as outcome measures in clinical trials for Parkinson's disease
24. Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease
25. Lessons learned
neuroprotective trials in Parkinson's disease
26. Lessons learned
symptomatic trials in early Parkinson's disease
27. Controversy
GPi vs STN deep brain stimulation in the management of Parkinson's disease
28. Controversy
ablative surgery vs deep brain stimulation in the management of Parkinson's disease
29. Controversy
mid-stage vs advanced stage deep brain stimulation in the management of Parkinson's disease
30. Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease
31. Lessons and challenges of trials for other non-motor complications of Parkinson's disease
32. Lessons and challenges of trials involving ancillary therapies for the management of Parkinson's disease
Index.